Anti-hRANKL-hIgG2

InvivoGen Kontakt z doradcą
Human RANKL (Denosumab) antibody - Human IgG2
Anti-hRANKL-hIgG2

Anti-hRANKL-hIgG2 mAb features a human IgG2 constant region (Fc) and the variable region of Denosumab which targets the transmembrane and soluble forms of the human RANKL (receptor activator of nuclear factor-κB ligand) antigen. RANKL is also known as member 11 of the tumor necrosis factor ligand superfamily (TNFSF11) [1]. RANKL binding to its receptor RANK induces signaling in osteoclasts and is responsible for bone resorption. RANKL-RANK also plays a pivotal role in dendritic cell maturation and T-cell differentiation [2]. 

Denosumab is a fully human IgG2 mAb that blocks the interaction of hRANKL with its receptor RANK and thus the downstream signaling. Human IgG2 is the second most common antibody present in serum. It is resistant to cleavage by proteolytic enzymes, due to a short hinge region. This isotype displays low complement-dependent cytotoxicity (CDC), very low antibody-dependent cellular phagocytosis (ADCP) and very low  antibody-dependent cellular cytotoxicity (ADCC).
Denosumab has been approved by the FDA for the treatment of osteoporosis and bone metastasis.

InvivoGen's Anti-hRANKL-hIgG2 is generated by recombinant DNA technology, produced in CHO cells, and purified by affinity chromatography (protein G).
More isotypes of this antibody are available and can be used for comparison of biological activities such as ADCC (see below). 

Read our review on Antibody Isotypes

References:

  1. Ahern E. et al., 2018. Roles of the RANKL-RANK axis in antitumour immunity -implications for therapy. Nat Rev Clin Oncol. 15(11):676-693.
  2. Cheng ML. & Fong L., 2014. Effects of RANKL-Targeted Therapy in Immunity and Cancer. Front Oncol. 3:329.

Podobne produkty

Anti-hCD40L

Anti-hCD40L

InvivoGen
Więcej
Anti-βGal-hCD3

Anti-βGal-hCD3

InvivoGen
Więcej
Anti-HLA Controls

Anti-HLA Controls

InvivoGen
Więcej